Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Receivables (2020 - 2025)

Historic Receivables for Oncology Institute (TOI) over the last 6 years, with Q3 2025 value amounting to $60.0 million.

  • Oncology Institute's Receivables rose 932.92% to $60.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.0 million, marking a year-over-year increase of 932.92%. This contributed to the annual value of $48.7 million for FY2024, which is 1344.64% up from last year.
  • According to the latest figures from Q3 2025, Oncology Institute's Receivables is $60.0 million, which was up 932.92% from $55.9 million recorded in Q2 2025.
  • In the past 5 years, Oncology Institute's Receivables ranged from a high of $60.0 million in Q3 2025 and a low of $21.2 million during Q4 2021
  • Over the past 5 years, Oncology Institute's median Receivables value was $47.8 million (recorded in 2023), while the average stood at $45.0 million.
  • In the last 5 years, Oncology Institute's Receivables surged by 9032.67% in 2022 and then plummeted by 1600.26% in 2025.
  • Oncology Institute's Receivables (Quarter) stood at $21.2 million in 2021, then skyrocketed by 90.33% to $40.4 million in 2022, then rose by 6.13% to $42.9 million in 2023, then rose by 13.45% to $48.7 million in 2024, then rose by 23.21% to $60.0 million in 2025.
  • Its Receivables was $60.0 million in Q3 2025, compared to $55.9 million in Q2 2025 and $49.7 million in Q1 2025.